痰热清注射液雾化吸入联合左氧氟沙星治疗高龄呼吸道感染患者的临床研究

Clinical Study on the Combination of Tanreqing Injection Nebulized Inhalation and Levofloxacin in the Treatment of Elderly Patients with Respiratory Tract Infections

目的:探讨痰热清注射液雾化吸入联合左氧氟沙星治疗高龄呼吸道感染患者的临床疗效及安全性分析。方法:选取2022年6月~2023年6月期间某院收治的104例呼吸道感染患者作为研究对象,按照随机数字表法分为对照组和观察组,每组52例。两组患者均接受氧气支持、祛痰止咳、纠正水电解质紊乱等常规治疗。对照组患者给予盐酸左氧氟沙星注射液治疗;观察组患者在对照组基础上给予痰热清注射液雾化吸入。两组均持续治疗1周。比较两组患者血清炎症因子[γ干扰素(IFN-γ)、白介素-4(IL-4)、白介素-5(IL-5)、肿瘤坏死因子-α(TNF-α)]、急性蛋白标志物[血清淀粉样蛋白A(SAA)、C反应蛋白(CRP)]和不良反应发生情况。结果:治疗后,两组患者血清IFN-γ、IL-4、IL-5、TNF-α水平均降低(P<0.05),且观察组低于对照组(P<0.05);两组患者血清SAA、CRP水平均降低(P<0.05),且观察组低于对照组(P<0.05);观察组患者恶心呕吐、食欲减退、注射部位发红及皮疹不良反应总发生率(5.77%)低于对照组(15.38%,P<0.05)。结论:在常规治疗的基础上,痰热清注射液雾化吸入联合左氧氟沙星治疗呼吸道感染,可有效减轻患者炎症反应,降低急性蛋白标志物水平,且未增加不良反应的发生风险。

Objective:To investigate the clinical efficacy and safety of Tanreqing injection combined with levofloxacin in the treatment of elderly patients with respiratory tract infection.Methods:104 patients with respiratory tract infection admitted to a hospital between June 2022 and June 2023 were assigned into the control group and the observation group by random number table method,with 52 patients each.Both groups received standard treatments including oxygen support,cough expectorants,correction of water and electrolyte imbalances.The control group received levofloxacin hydrochloride injection,while the observation group received Tanreqing injection via atomized inhalation based on the control group.Both groups underwent continuous treatment for a week.Serum levels of inflammatory factors[interferon-γ(IFN-γ),interleukin-4(IL-4),interleukin-5(IL-5),tumor necrosis factor-α(TNF-α)]and acute protein markers[serum amyloid A(SAA),C reactive protein(CRP)]and the incidence of adverse reactions were compared between the two groups.Results:Following treatment,serum levels of IFN-γ,IL-4,IL-5,and TNF-αdecreased in both groups(P<0.05),with the observation group showing lower levels than the control group(P<0.05).Serum levels of SAA and CRP decreased in both groups(P<0.05),with the observation group exhibiting lower levels than the control group(P<0.05).The total incidence of adverse reactions such as nausea,vomiting,loss of appetite,redness at the injection site and rash in the observation group(5.77%)was lower than that in the control group(15.38%,P<0.05).Conclusion:The combination of Tanreqing injection with levofloxacin in the treatment of respiratory tract infection,on the basis of conventional therapy,effectively reduces patients'inflammatory response,lowers acute protein marker levels,and does not elevate the risk of adverse reactions.